Literature DB >> 23847349

Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.

Ramiro Iglesias-Bartolome1, Daniel Martin, J Silvio Gutkind.   

Abstract

SUMMARY: Two studies published in this issue of Cancer Discovery describe the emerging mutational landscape of head and neck squamous cell carcinomas (HNSCC) and their genomic and epigenetic alterations, thus identifying novel actionable cancer drivers and predictive biomarkers for targeted therapies. Most genomic alterations in HNSCC converge in a handful of molecular pathways, resulting in cell-cycle deregulation, genomic instability, cell differentiation defects, and persistent mitogenic signaling, the latter involving aberrant phosphoinositide 3-kinase (PI3K)/mTOR pathway activation, thereby rendering HNSCC responsive to PI3K/mTOR inhibitors. Cancer Discov; 3(7); 722-5. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23847349      PMCID: PMC4348071          DOI: 10.1158/2159-8290.CD-13-0239

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  12 in total

1.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Authors:  Alfredo A Molinolo; Christina Marsh; Mohamed El Dinali; Nitin Gangane; Kaitlin Jennison; Stephen Hewitt; Vyomesh Patel; Tanguy Y Seiwert; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2012-03-12       Impact factor: 12.531

2.  Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.

Authors:  Floyd Christopher Holsinger; Sarina Anne Piha-Paul; Filip Janku; David S Hong; Johnique T Atkins; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

Review 3.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 4.  The molecular biology of head and neck cancer.

Authors:  C René Leemans; Boudewijn J M Braakhuis; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

5.  Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.

Authors:  Nishant Agrawal; Mitchell J Frederick; Curtis R Pickering; Chetan Bettegowda; Kyle Chang; Ryan J Li; Carole Fakhry; Tong-Xin Xie; Jiexin Zhang; Jing Wang; Nianxiang Zhang; Adel K El-Naggar; Samar A Jasser; John N Weinstein; Lisa Treviño; Jennifer A Drummond; Donna M Muzny; Yuanqing Wu; Laura D Wood; Ralph H Hruban; William H Westra; Wayne M Koch; Joseph A Califano; Richard A Gibbs; David Sidransky; Bert Vogelstein; Victor E Velculescu; Nickolas Papadopoulos; David A Wheeler; Kenneth W Kinzler; Jeffrey N Myers
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

Authors:  Panomwat Amornphimoltham; Vyomesh Patel; Akrit Sodhi; Nikolaos G Nikitakis; John J Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

7.  Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.

Authors:  Curtis R Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M Neskey; Mei Zhao; Marcus V Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-Xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J Issa; Patrick A Zweidler-McKay; Xifeng Wu; Adel K El-Naggar; John N Weinstein; Jing Wang; Donna M Muzny; Richard A Gibbs; David A Wheeler; Jeffrey N Myers; Mitchell J Frederick
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

8.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

9.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

10.  PTEN deficiency contributes to the development and progression of head and neck cancer.

Authors:  Cristiane H Squarize; Rogerio M Castilho; Aline C Abrahao; Alfredo Molinolo; Mark W Lingen; J Silvio Gutkind
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

View more
  54 in total

1.  Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.

Authors:  Vicente Pérez-García; Javier Redondo-Muñoz; Amit Kumar; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2014-06-23       Impact factor: 4.272

2.  Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.

Authors:  Pilar Bayo; Adriana Jou; Albrecht Stenzinger; Chunxuan Shao; Madeleine Gross; Alexandra Jensen; Niels Grabe; Christel Herold Mende; Pantelis Varvaki Rados; Juergen Debus; Wilko Weichert; Peter K Plinkert; Peter Lichter; Kolja Freier; Jochen Hess
Journal:  Mol Oncol       Date:  2015-05-20       Impact factor: 6.603

3.  Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.

Authors:  Adam D Swick; Prashanth J Prabakaran; Margot C Miller; Amal M Javaid; Michael M Fisher; Emmanuel Sampene; Irene M Ong; Rong Hu; Mari Iida; Kwangok P Nickel; Justine Y Bruce; Deric L Wheeler; Randall J Kimple
Journal:  Mol Cancer Ther       Date:  2017-04-26       Impact factor: 6.261

4.  Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Authors:  Hannah Carter; Rachel Marty; Matan Hofree; Andrew M Gross; James Jensen; Kathleen M Fisch; Xingyu Wu; Christopher DeBoever; Eric L Van Nostrand; Yan Song; Emily Wheeler; Jason F Kreisberg; Scott M Lippman; Gene W Yeo; J Silvio Gutkind; Trey Ideker
Journal:  Cancer Discov       Date:  2017-02-10       Impact factor: 39.397

5.  IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells.

Authors:  Chai Phei Gan; Kin Kit Sam; Pei San Yee; Nur Syafinaz Zainal; Bernard Kok Bang Lee; Zainal Ariff Abdul Rahman; Vyomesh Patel; Aik Choon Tan; Rosnah Binti Zain; Sok Ching Cheong
Journal:  Cell Oncol (Dordr)       Date:  2019-04-04       Impact factor: 6.730

6.  Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Authors:  Terry A Day; Keisuke Shirai; Paul E O'Brien; Maria Gisele Matheus; Kristina Godwin; Amit J Sood; Anvesh Kompelli; Julie A Vick; Daniel Martin; Lynn Vitale-Cross; Juan Luis Callejas-Varela; Zhiyong Wang; Xingyu Wu; Olivier Harismendy; Alfredo A Molinolo; Scott M Lippman; Carter Van Waes; Eva Szabo; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

7.  PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.

Authors:  Vaishnavi Sambandam; Mitchell J Frederick; Li Shen; Pan Tong; Xiayu Rao; Shaohua Peng; Ratnakar Singh; Tuhina Mazumdar; Chenfei Huang; Qiuli Li; Curtis R Pickering; Jeffery N Myers; Jing Wang; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2019-02-15       Impact factor: 12.531

Review 8.  Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Authors:  Sayuri Miyauchi; Sangwoo S Kim; John Pang; Kathryn A Gold; J Silvio Gutkind; Joseph A Califano; Loren K Mell; Ezra E W Cohen; Andrew B Sharabi
Journal:  Clin Cancer Res       Date:  2019-02-27       Impact factor: 12.531

9.  Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.

Authors:  Mara Gilardi; Zhiyong Wang; Marco Proietto; Anastasia Chillà; Juan Luis Calleja-Valera; Yusuke Goto; Marco Vanoni; Matthew R Janes; Zbigniew Mikulski; Antonio Gualberto; Alfredo A Molinolo; Napoleone Ferrara; J Silvio Gutkind; Francis Burrows
Journal:  Mol Cancer Ther       Date:  2020-07-29       Impact factor: 6.261

10.  mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model.

Authors:  Juan Luis Callejas-Valera; Ramiro Iglesias-Bartolome; Panomwat Amornphimoltham; Julia Palacios-Garcia; Daniel Martin; Joseph A Califano; Alfredo A Molinolo; J Silvio Gutkind
Journal:  Carcinogenesis       Date:  2016-08-18       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.